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STUDY QUESTION: Does standardised treatments used in children and adolescents with haematologic malignancies, including acute
lymphoblastic (ALL) or myeloid leukaemia (AML) and non-Hodgkin lymphoma (NHL), affect endocrine function of the developing testes?
SUMMARY ANSWER: Therapy of haematologic malignancies do not provoke an overt damage of Sertoli and Leydig cell populations, as
revealed by normal levels of anti-Müllerian hormone (AMH) and testosterone, but a mild primary testicular dysfunction may be observed,
compensated by moderate gonadotropin elevation, during pubertal development.
WHAT IS KNOWN ALREADY: Evidence exists on the deleterious effect that chemotherapy and radiotherapy have on germ cells, and
some attention has been given to the effects on Leydig and Sertoli cells of the adult gonads, but information is virtually non-existent on the
effects of oncologic treatment on testicular somatic cell components during childhood and adolescence.
STUDY DESIGN, SIZE, DURATION: A retrospective, analytical, observational study included 97 boys with haematological malignancies
followed at two tertiary paediatric public hospitals in Buenos Aires, Argentina, between 2002 and 2015.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Clinical records of males aged 1–18 years, referred with the diagnoses of ALL,
AML or NHL for the assessment of gonadal function, were eligible. We assessed serum levels of AMH and FSH as biomarkers of Sertoli cell
endocrine function and testosterone and LH as biomarkers of Leydig cell function.
MAIN RESULTS AND THE ROLE OF CHANCE: All hormone levels were normal in the large majority of patients until early pubertal
development. From Tanner stage G3 onwards, while serum AMH and testosterone kept within the normal ranges, gonadotropins reached
mildly to moderately elevated values in up to 35.9% of the cases, indicating a compensated Sertoli and/or Leydig cell dysfunction, which
generally did not require hormone replacement therapy.
LIMITATIONS, REASONS FOR CAUTION: Serum inhibin B determination and semen analysis were not available for most patients;
therefore, we could not conclude on potential fertility impairment or identify whether primary Sertoli cell dysfunction resulted in secondary
depleted spermatogenesis or whether primary germ cell damage impacted Sertoli cell function.
WIDER IMPLICATIONS OF THE FINDINGS: The regimens used in the treatment of boys and adolescents with ALL, AML or NHL
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may be observed, usually compensated by slightly elevated gonadotropin secretion by the pituitary in adolescents, and not requiring hormone
replacement therapy. No clinically relevant risk factor, such as severity of the disease or treatment protocol, could be identified in association
with the compensated endocrine dysfunction.
STUDY FUNDING/COMPETING INTEREST(S): This work was partially funded by grants PIP 11220130100687 of Consejo Nacional
de Investigaciones Científicas y Técnicas (CONICET) and PICT 2016-0993 of Fondo para la Investigación Científica y Tecnológica (FONCYT),
Argentina. R.A.R., R.P.G. and P.B. have received honoraria from CONICET (Argentina) for technology services using the AMH ELISA. L.A.A.
is part-time employee of CSL Behring Argentina. The other authors have no conflicts of interest to disclose.
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Introduction
Haematologic malignancies account for almost 40% of paediatric can-
cers (Armstrong et al., 2016), with an annual incidence of ∼30 cases
per million children and adolescents <20 years of age (Hunger and
Mullighan, 2015). Acute lymphoblastic leukaemia (ALL), the most
prevalent paediatric malignancy, occurs more frequently in children of
Latin/Hispanic ancestries compared with other ancestries in the United
States (Lim et al., 2014), with a slight predominance in males (Hunger
and Mullighan, 2015).
The use of effective chemotherapy and radiotherapy for the man-
agement of childhood cancer has resulted in remarkable improve-
ments in overall survival over the past decades. The 5-year sur-
vival rate for ALL, acute myeloid leukaemia (AML) and non-Hodgkin
lymphoma (NHL) has increased to ∼90% following the develop-
ment of intensive multi-drug, induction and consolidation regimens
including intrathecal chemotherapy (Hunger and Mullighan, 2015). This
marked improvement in therapy has led to a growing population of
childhood cancer survivors, who are subject to long-term sequelae
impacting on health issues, the most frequent being endocrine disor-
ders (Crowne et al., 2015). In particular, cancer treatment can affect
reproductive function, and loss of fertility has become an important
concern.
The adult testis produces spermatozoa and hormones. Spermatozoa
arise from germ cells within the seminiferous tubules, whereas hor-
mones are secreted by specific somatic cell populations: androgens by
Leydig cells present in the interstitial tissue and inhibin B by Sertoli
cells located within the seminiferous tubules, where they also give
functional support to germ cells. In the prepubertal gonad, the germ cell
population is represented exclusively by pre-meiotic spermatogonia
that self-renew by mitosis, while immature Sertoli cells produce anti-
Müllerian hormone (AMH) and inhibin B, and mature Leydig cells are
absent owing to the lack of LH stimulation (Rey, 2014, Stukenborg
et al., 2018).
A large amount of evidence exists on the deleterious effect that
chemotherapy agents and irradiation reaching the testes have on
germ cells that have a high mitotic rate (reviewed by Jahnukainen
and Stukenborg, 2012, Gebauer et al., 2018 and Kesari et al., 2018).
Some attention has been focused on the effects of chemotherapy
and radiotherapy on the Leydig (Brämswig et al., 1990, Heikens
et al., 1996, Kenney et al., 2012) and Sertoli (Heikens et al., 1996,
Bar-Shira Maymon et al., 2004, Bordallo et al., 2004, van Beek
et al., 2007, Lahteenmaki et al., 2008, Cuny et al., 2011, Laporte
et al., 2011) cell populations of the adult gonads and to late effects



































































































treatments during childhood. Leydig and Sertoli cell failure seems
relatively rare after chemotherapy in the adult and involves a
significantly higher irradiation dose than that required to cause germ
cell damage. Conversely, information is virtually non-existent on the
effects of cancer treatment on the somatic cell components of the
prepubertal testis (reviewed by Stukenborg et al., 2018 and Allen et al.,
2018).
Recent research on the effects of cancer treatment has focused on
preventing damage. However, this is challenging for prepubertal males
for whom fertility preservation is not possible given that they do not
produce spermatozoa that can be cryopreserved. Some centres have
started to cryopreserve spermatogonial stem cells, which could be
transplanted back into the testes later in life and give rise to sperm
(Stukenborg et al., 2018). Nonetheless, normal function of the Sertoli
and Leydig cells exposed to cancer treatment would be essential for
the success of this therapeutic approach. Furthermore, endocrine
testicular function is important for pubertal development, especially
for the achievement of a normal growth spurt and bone mass accrual
(Sklar et al., 2018).
In this work, we aimed to determine whether the oncologic treat-
ments used in prepubertal and pubertal boys with ALL, AML or NHL,
the set of most frequent paediatric cancers, affect the endocrine
function of the somatic component of the developing testis. In an
observational study on a large cohort of patients treated before or
after the age of 10 years, with long-term follow-up, we assessed serum
levels of AMH and FSH as direct and indirect biomarkers respectively
of Sertoli cell function, and testosterone and LH as direct and indirect
biomarkers respectively of Leydig cell function.
Materials and methods
Study design and setting
We performed a retrospective, analytical, observational study at
Ricardo Gutiérrez and Pedro de Elizalde Children’s Hospitals, two
tertiary paediatric public hospitals in Buenos Aires, Argentina. Clinical
and laboratory data were extracted from the clinical charts.
The diagnoses of haematologic malignancies were made according to
the third and fourth editions of the World Health Organisation Classi-
fication of Tumours of Haematopoietic and Lymphoid Tissues (Arber
et al., 2016). For patients with ALL, risk stratification and treatment
were assigned according to the ALL IC-BFM 2002 intercontinental trial
(Stary et al., 2014). Briefly, three risk groups were defined: standard









rep/dez216/5643515 by guest on 26 N
ovem
ber 2019
Chemotherapy and paediatric testicular function 3
Patients
Inclusion criteria
All clinical records of males aged 1–18 years, referred with the diag-
noses of ALL, AML or NHL from the Units of Haematology to the
Divisions of Endocrinology of Ricardo Gutiérrez and Pedro de Elizalde
Children’s Hospital for the assessment of gonadal function between
2002 and 2015, were eligible.
Exclusion criteria
Clinical records were excluded from the analysis when the malignancy
involved the central nervous system or the testes, in cases of trisomy
21 (Grinspon et al., 2011) or in any other condition known to affect
the hypothalamic–pituitary–testicular axis (Rey et al., 2013), in order
to avoid potential confusion due to known causes of central or primary
hypogonadism.
Outcome measures and definitions
Two different analyses were performed. For the cross-sectional
analysis, clinical records were included for patients with at least 1 year
of follow-up after the end of chemotherapy and one endocrine
assessment of testicular function (including serum levels of AMH,
testosterone, FSH and LH) between 1 and 8 years after the end
of chemotherapy. For the longitudinal study, all clinical records
were included. For the analyses of serum hormones, patients were
grouped according to pubertal stages as defined by Marshall and
Tanner (1970). Owing to the retrospective design of the study,
testicular volume, genital development and pubic hair staging were
obtained from the history charts as reported by the patient’s paediatric
endocrinologist. Testicular volume was obtained by comparison with
Prader’s orchidometer, with the inter-individual variability inherent to
the assessment method.
The main outcome measures of the study were the serum
concentrations of AMH, testosterone, FSH and LH. Values were
expressed in absolute levels and as standard deviation scores (SDS)
based on age- and Tanner genital stage-matched reference ranges
(see Supplementary Table SI), previously published by our laboratory
(Grinspon et al., 2011, Grinspon et al., 2012b). Values of AMH and
testosterone below −2 SDS were considered direct markers of
affected testicular function. Values of FSH and LH above +2 SDS
were considered indirect markers of affected testicular function. The
use of SDS allowed the analysis of the whole cohort, whereas the
use of absolute levels required a subgroup analysis by age and Tanner
genital stage.
For the primary analysis, exposure measures, i.e. chemotherapy and
radiotherapy, were analysed together and separately. Due to the ret-
rospective design of our study, we did not have clinical Tanner staging
data at the end of treatment, since patients were referred for endocrine
assessment after the end of oncologic treatment. We intended to
assess separately the effect of cancer treatment on boys who received
the whole treatment at a prepubertal period, i.e. when the hypotha-
lamic–pituitary–testicular axis is mainly quiescent (low mitotic index
for all cell types), and on boys who were more likely exposed to a
reactivated axis (characterised by a higher mitotic index in testicular
cells). The classical clinical signs of pubertal onset, i.e. testicular volume
and Tanner stages, were not used for categorising patients at the






























































































































Figure 1 Flow chart of patient inclusion in the study.
testicular size and pubertal development (Crowne et al., 2015). Like
other authors (Romerius et al., 2011), we chose to use an age cut-off of
10 years based on population studies indicating that in boys <10 years
of age the likelihood of having started pubertal development is <5%
(Tomova et al., 2010) and the classical Tanner study indicating that at
9.5 years <2.5% of boys have reached G2 (Marshall and Tanner, 1970).
Therefore, two subgroups were considered, according to the age at
which chemotherapy or radiotherapy ended: <10 years old (Group
A) and ≥10 years old (Group B).
Hormone assays
Hormonal values were extracted from the clinical charts and the
laboratory Cobas® Infinity system (Roche). The AMH assay for all
samples (Ricardo Gutiérrez and Pedro de Elizalde Children’s Hospitals)
was centralised in the Ricardo Gutiérrez laboratory. Gonadotropin and
testosterone measurements were performed in both hospitals, using
the same methods.
AMH
Serum AMH was determined using an enzyme-linked immunoassay
specific for human AMH (EIA AMH/MIS®, Beckman-Coulter Co.,
Marseilles, France), as previously validated by our group (Grinspon
et al., 2011, Grinspon et al., 2012b). Intra- and inter-assay coefficients
of variation were, respectively, 10.5% and 9.4% for a serum AMH
concentration of 700 pmol/l, and 11.1% and 12.8% for a serum
AMH concentration of 7 pmol/l. When serum AMH levels were
undetectable, a value of 1 pmol/l, corresponding to the limit of
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Table I Characteristics of the whole study sample.
Whole sample (n = 97) Acute Lymphoid
Leukaemia (n = 83)
Acute Myeloid
Leukaemia (n = 5)
Non-Hodgkin
Lymphoma (n = 9)...........................................................................................................................................................................









































































































Group A: patients in whom chemotherapy ended before the age of 10 years.
Group B: patients in whom chemotherapy ended at age 10 years or more.
∗Values represent median (range).
Gonadotropins
LH and FSH were determined using electro-chemiluminescent
immunoassays (ECLIA, Roche Diagnostics GmbH, Mannheim,
Germany) as described (Grinspon et al., 2012b). The limits of
quantification of both LH and FSH assays were 0.10 IU/l, according
to the 2nd National Institute for Biological Standards and Control
International Standard 80/552 for LH and the 2nd World Health
Organisation International Reference Preparation 78/549 for FSH.
Intra- and inter-assay coefficients of variation were 1.1% and 1.8% for
LH, respectively, for a mean LH concentration of 2.8 IU/l and 1.4% and
1.5% for a mean LH concentration of 16.9 IU/l. Intra- and inter-assay
coefficients of variation were 1.0% and 4.2% for FSH, respectively,
for a mean FSH concentration of 14.8 IU/l and 1.1% and 4.1% for a
mean FSH concentration of 23.4 IU/l. When serum LH or FSH levels





































Testosterone was determined in serum using an electro-
chemiluminescent immunoassay (ECLIA, Roche Diagnostics GmbH,
Mannheim, Germany) as described (Grinspon et al., 2011). Intra- and
inter-assay coefficients of variation were 2.4% and 2.6%, respectively,
for a mean testosterone concentration of 176 ng/dl (6.10 nmol/l) and
1.2% and 2.3% for a mean testosterone concentration of 455 ng/dl
(15.78 nmol/l). When serum testosterone levels were undetectable,
a value of 10 ng/dl (0.347 nmol/l), corresponding to the limit of
quantification (functional sensitivity), was attributed.
Statistical analyses
Data distribution was assessed for normality using the Shapiro–Wilk
test. Results are expressed as median and range. Because non-Gaussian
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Table II Characteristics of the study sample included in the cross-sectional analysis.
Whole sample (n = 61) Acute Lymphoid
Leukaemia (n = 50)
Acute Myeloid
Leukaemia (n = 5)
Non-Hodgkin
Lymphoma (n = 6)...........................................................................................................................................................................







































































































Group A: patients in whom chemotherapy ended before the age of 10 years.
Group B: patients in whom chemotherapy ended at age 10 years or more.
∗Values represent median (range).
for comparisons. Fisher’s exact test was used to compare categorical
variables. To assess the existence of association between chemother-
apy agent cumulative doses and gonadal dysfunction, a logistic regres-
sion model was used, considering cumulative doses as continuous
variables and gonadal dysfunction as dichotomised (FSH or LH >+2
SDS considered as gonadal dysfunction; ≤+2 SDS considered as
normal). Odds ratios and 95% confidence intervals for the final model
were reported. The level of significance was set at P < 0.05. All
statistical analyses were performed using GraphPad Prism version 8.02
for Windows (GraphPad Software, San Diego, CA, USA) and STATA
13 (StataCorp LLC, College Station, TX, USA).
Ethical issues
Research was conducted in accordance with principles of the Decla-
ration of Helsinki. The study protocol was approved by the Institu-




































Children’s Hospitals, Buenos Aires. Because the study was based on
a retrospective clinical chart review with descriptive purposes and
no anticipated effect on prognosis or therapeutic management of the
patients whose charts were included, the need for a written informed
consent was waived.
Results
Characteristics of the study sample
Our database contained 148 eligible males with a diagnosis of ALL,
AML or NHL, endocrinologically assessed between 2002 and 2015
(Fig. 1). Due to incomplete medical records or endocrine assessment,
38 could not be included and 13 patients were excluded because
they were highly likely to have hypothalamic–pituitary–testicular
involvement prior to the initiation of treatment for ALL, AML or NHL:
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Figure 2 Serum levels of AMH, testosterone and gonadotropins in the 61 boys with ALL, AML or NHL included in the cross-
sectional study. Patients are grouped according to age or pubertal Tanner stage at the moment of hormone determination. One value per patient
obtained no earlier than 1 year after the end of chemotherapy. (A) Values expressed as SDS for age and Tanner genital stage. (B) Absolute values;
the grey areas represent normal reference levels for age and Tanner genital stage. Both A and B are according to Grinspon et al., 2011. ALL: acute
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Figure 3 Serum levels of AMH, testosterone and
gonadotropins,expressed as SDS for age in the 61 boys with
ALL, AML or NHL included in the cross-sectional study.
Values are expressed as SDS for age (see Supplementary Table SII).
One value per patient obtained no earlier than 1 year after the end
of chemotherapy. Group A: patients in whom chemotherapy ended
before the age of 10 years. Group B: patients in whom chemotherapy
ended at age 10 years or more. Dotted lines represent 0, +2 and
−2 SDS for age and Tanner genital stage. ALL: acute lymphoblastic
leukaemia; AML: acute myeloid leukaemia; NHL: non-Hodgkin
lymphoma.
the malignant disease and 1 patient with trisomy 21 (Grinspon et al.,
2011). Therefore, 97 paediatric male patients, i.e. 65.5% of those in
our database, were analysed: 83 with ALL, 5 with AML and 9 with
NHL. As expected, common B-cell ALL was the most prevalent form.
Patients classified with SR and IR, and thus receiving a similar treatment
protocol, were the vast majority: they represented 90% of patients with
ALL and 77% of all patients in the study (Table I). Regarding hospital
origin, 76 patients were recruited at Ricardo Gutiérrez Children’s
Hospital (65 ALL, 2 AML and 9 NHL) and 21 at Pedro de Elizalde
Children’s Hospital (18 ALL, 3 AML).
As expected, patients with ALL and AML were slightly younger
at diagnosis and at end of chemotherapy than those with NHL.
Most patients with ALL (61.4%) or with AML (80%), whereas only
33.3% of patients with NHL, were younger than 10 years at the end
of treatment (Group A). The age at endocrine assessment for the
cross-sectional part of the study was also lower in patients with
ALL and AML: 38.0% and 40.0% respectively were still younger
than 10 years when hormonal studies were performed after at
least 1 year of follow-up after the end of the last chemotherapy
phase (Table II). Bone marrow transplantation (BMT) preconditioning,
including total body irradiation (12–18 Gy), was performed in six
cases of ALL, and radiotherapy (12–24 Gy) was performed in 11
cases of ALL and 3 of AML (Table III and Supplementary Table II).
The cumulative doses of chemotherapy agents are described in
Table III: patients with HR ALL and with AML or NHL received ∼2-
fold higher cumulative doses of IV methotrexate and 10-fold higher
cumulative doses of C-arabinoside, and were the only ones who
received ifosfamide and etoposide. Pegasparagase and erwinase were






























































































































Figure 4 Mean bilateral testicular volume in the 61 boys
with ALL,AML or NHL included in the cross-sectional study.
Patients are grouped according to age or pubertal Tanner stage at the
moment of clinical assessment of testicular volume. One value per
patient obtained no earlier than 1 year after the end of chemotherapy.
The grey areas represent normal reference values, according to (Grin-
spon et al., 2011). ALL: acute lymphoblastic leukaemia; AML: acute
myeloid leukaemia; NHL: non-Hodgkin lymphoma.
Three patients received levothyroxine supplementation due to
hypothyroidism, and one patient received treatment with growth
hormone.
Cross-sectional study
There were 61 patients, with at least 1 year of follow-up after the
end of chemotherapy and one endocrine assessment of testicular
function between 1 and 8 years after the end of chemotherapy,
included in the cross-sectional analysis (Table II). Laboratory results
from the first assessment available in that period were used. Because
serum values of hormones of the gonadal axis vary with age in normal
boys during infancy and childhood, values were analysed using SDS
for age and pubertal stage groups in the overall evaluation. In the
age and pubertal stage subgroup analyses, absolute serum levels and
SDS were used.
When the analysis was performed according to the age and Tanner
pubertal stage at endocrine assessment, FSH and/or LH elevation was
observed in 13 patients (Fig. 2). Gonadotropin elevation was mild to
moderate and was noticed mainly in the older groups (Tanner stages
4–5). Eleven of them had suffered from ALL (three SR and eight IR)
and two had suffered from NHL (Burkitt). Only two of these patients
with gonadotropin elevation had required total body irradiation
and BMT.
Serum levels of AMH, a direct Sertoli cell biomarker, were within the
normal levels in all 37 patients treated for ALL, AML or NHL before
the age of 10 years (Group A) (Figs 2 and 3). FSH was also normal
in the vast majority, and only slightly above the reference range for
age in three cases (Fig. 3). Two of them were already >10 years old
when hormone levels (FSH 3.8 and 8.6 IU/l) were first assessed at least
1 year after the end of chemotherapy and had testosterone levels (12
and 143 ng/dl, respectively) compatible with pubertal onset (Fig. 2).
All three had a diagnosis of SR ALL, and none of them had received
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Time aer end of chemotherapy (years) 
Figure 5 Progression with time after the end of chemotherapy of serum levels of AMH, testosterone and gonadotropins,
expressed as SDS for age and Tanner genital stage in the 97 boys with ALL, AML or NHL included in the longitudinal follow-
up study.Values are expressed as SDS for age and Tanner genital score, according to Grinspon et al., 2011. Group A: patients in whom chemotherapy
ended before the age of 10 years. Group B: patients in whom chemotherapy ended at age 10 years or more. ALL: acute lymphoblastic leukaemia; AML:
acute myeloid leukaemia; NHL: non-Hodgkin lymphoma.
Serum levels of testosterone and LH, reflecting Leydig cell function,
were within the normal levels in all patients treated for ALL, AML or
NHL before the age of 10 years (Group A). However, one patient
was first assessed at the age of 11.7 years: since testicular volume was
2 ml bilaterally, he was clinically classified as G1, yet hormonal values
were already typical of G2 (LH 1.9 IU/l, FSH 0.9 IU/l, testosterone
144 ng/dl). Testicular volume was slightly below normal (10 ml) in only
one patient of this group at Tanner stage G4 (Fig. 4), yet he had normal
hormone levels.
Given that primary gonadal damage may not elicit gonadotropin
elevation during childhood, we performed a subanalysis of those



























during puberty, at Tanner stage ≥G3: one of six patients had
elevated FSH and all had normal LH. Altogether, these results
suggest that treatment for childhood cancer before the age of
10 years did not significantly affect testicular endocrine function
assessed >1 year after the end of treatment in the majority of
the cases.
In the 24 patients in whom treatment ended at an age above
10 years (Group B), i.e. more likely to have a reactivated hypothalamic–
pituitary–gonadal axis, AMH was never found below the reference
range but FSH was elevated in eight cases, suggesting the occurrence
of a compensated primary Sertoli cell insufficiency. In two patients, one








rep/dez216/5643515 by guest on 26 N
ovem
ber 2019
10 Grinspon et al.
Figure 6 Progression with age of absolute serum levels of AMH, testosterone and gonadotropins in the 97 boys with ALL, AML
or NHL included in the longitudinal follow-up study. Group A: patients in whom chemotherapy ended before the age of 10 years. Group B:
patients in whom chemotherapy ended at age 10 years or more. The grey areas represent normal reference values, according to Grinspon et al., 2011.
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Table IV Logistic regressions for chemotherapy agent cumulative doses as independent variables
and FSH or LH as dichotomized variables (> +2 SDS considered as affected; ≤ +2 SDS considered
as normal) in 97 patients.
FSH (SDS) LH (SDS)
.............................................. ...................................................
Odds Ratio 95% CI P Odds Ratio 95% CI P
......................................................................................................................................................
Cyclophosphamide (g/m2) 1.42 0.58–3.51 0.45 2.68 0.55–13.07 0.22
Ifosfamide (g/m2) 0.73 0.35–1.54 0.41 0.04 0.004–0.57 0.017
Methotrexate IV (g/m2) 1.09 0.98–1.21 0.12 1.49 0.99–2.25 0.054
Methotrexate oral (g/m2) 3.25 0.78–13.36 0.10 9.63 0.55–169.17 0.12
6-Mercaptopurine (g/m2) 0.92 0.83–1.02 0.13 0.84 0.68–1.03 0.09
6-Thioguanine (g/m2) 0.92 0.22–3.86 0.91 0.001 0.0001–0.45 0.026
C-Arabinoside (g/m2) 1.37 0.23–8.11 0.73 730.22 2.80–190 279 0.020
Doxorubicin (g/m2) 1.00 0.97–1.02 0.93 1.14 1.00–1.30 0.044
Daunorubicin (g/m2) 1.00 0.99–1.02 0.37 0.97 0.91–1.02 0.19
Vincristine (mg/m2) 1.10 0.93–1.30 0.26 1.20 0.83–1.75 0.33
L-Asparaginase (g/m2) 1.00 0.99–1.00 0.41 1.00 0.99–1.00 0.68
Etoposide (mg/m2) 1.00 0.99–1.00 1.00 1.01 1.00–1.03 0.037
Erwinase (IU/m2) 1.00 0.99–1.00 0.56 0.99 0.99–1.06 0.99
Pegaspargase (U/m2) 0.99 0.99–1.00 0.18 0.48 0.99–1.00 0.48
the upper normal range (Fig. 3B); the observation was not considered
clinically significant, although a mild degree of Sertoli cell immaturity
cannot be ruled out.
Similarly, testosterone levels were within the reference range in all 24
cases, but LH were slightly elevated in five patients receiving treatment
after the age of 10 years (Group B), probably indicating a compensated
Leydig cell dysfunction (Fig. 3). All these patients were at pubertal
stages Tanner G4–5 (Fig. 2). Testicular volume was below normal in
five patients at pubertal stages Tanner G4–5 (Fig. 4). Two of them had
an elevation of both gonadotropins, one of whom had a relapse leading
to BMT.
Longitudinal study
All 97 patients were included in the longitudinal analysis. Median
elapsed time between the end of treatment and the first hormonal
assessment was 3.1 years in the whole study sample, ranging from 0.1
to 11.9 years (Table I). Longitudinal data were available for 58 patients
who completed treatment before the age of 10 years (Group A) and
for 39 who received treatment beyond the age of 10 years (Group B).
Serum AMH was never <2 SDS for up to 12 years of follow-up (Fig. 5)
or below the reference range for age (Fig. 6) in patients of Groups A or
B, during the whole follow-up. In two cases (Fig. 5), serum AMH was
slightly above the upper normal limit for age. Whether this represents
a slightly delayed pubertal development could not be ascertained with
the available data. Testosterone remained below the reference range
in only one pubertal patient.
In Group A, eleven of 58 patients showed at least one serum FSH
and/or LH value above the normal range. The elevation was transient
in two cases and persistent in nine (15.5%): FSH was elevated in eight
patients (13.8%), suggesting a compensated dysfunction of the tubular






































































of compensated Leydig cell dysfunction (Supplementary Table II). Nine
patients had ALL (six SR and three IR), two of whom had been
exposed to BMT preconditioning (one SR and one IR); these two
patients had both gonadotropin levels above the normal range for
their respective pubertal stage. Testicular volume remained below the
expected value in one patient at age 15 years. In another case, testic-
ular volume was initially low but recovered as pubertal development
progressed (Fig. 6).
In Group B, 17 of 39 patients showed at least one elevated
gonadotropin value. In 14 cases (35.9%), the elevation was present in
the last available assessment: FSH was elevated in 11 (28.2%) and LH in
10 (25.6%) (Supplementary Table II). Thirteen patients had ALL (11 IR
and 2 HR), two of whom had been exposed to BMT preconditioning
(two IR), and one had NHL. No patient with AML was affected.
Testicular volume remained below the expected value in five cases
(Fig. 6).
A subanalysis was performed to compare the proportion of
gonadotropin elevation between patients of Group A with follow-
up until Tanner stage ≥G3 (n = 23) and Group B (n = 39). We found
no statistically significant difference regarding FSH elevation (Group A,
21.7%; Group B, 28.2%; Fisher’s exact test, P = 0.40) or LH elevation
(Group A, 17.4%; Group B, 25.6%; Fisher’s exact test, P = 0.42).
We assessed the association between cumulative doses of
chemotherapy agents and the occurrence of gonadal dysfunction.
Multiple regression analysis showed that no statistically significant
associations were found when patients were categorised into affected
Sertoli cell dysfunction (FSH >+2 SDS) or not (FSH ≤+2 SDS)
(Table IV). For Leydig cell dysfunction (i.e. LH >+2 SDS), exposure to
C-arabinoside appeared as a significant risk factor, whereas exposures
to doxorubicin and etoposide marginally increased the odds ratio.
Conversely, thioguanine and ifosfamide were associated with a
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of gonadotropin elevation was similar in the three risk groups of ALL:
SR, 22.2%; IR, 33.3%; and HR, 37.5%.
Discussion
In this large study, with prolonged follow-up, we show that oncologic
therapy for haematologic malignancies in boys and adolescents
did not provoke an overt primary hypogonadism, as revealed
by the persistence of normal levels of direct biomarkers of
Sertoli cells (AMH) and Leydig cells (testosterone). However, a
compensated Sertoli and Leydig cell dysfunction was evidenced
by a mild to moderate gonadotropin elevation during pubertal
development in up to 35.9% of the cases. No clinically relevant
risk factor, such as severity of the disease or treatment protocol,
could be identified in association with the compensated endocrine
dysfunction.
Most studies assessing gonadal toxicity of cancer therapy in male
adolescents and adults have focused on germ cell toxicity, and iden-
tified alkylating agents (busulphan, cyclophosphamide and ifosfamide)
in high doses and cis-platinum as high or moderate risk for sper-
matogenic damage. Our cohort included only patients exposed to
the ALL IC-BFM 2002 intercontinental trial protocol adopted by the
Argentine Group for the Treatment of Acute Leukaemia (GATLA,
Grupo Argentino de Tratamiento de la Leucemia Aguda; Sociedad
Argentina de Hematología, 2013). This therapy regimen uses mostly
drugs classified as of low risk for spermatogenic toxicity and doses
of alkylating agents, like cyclophosphamide and ifosfamide, which are
below the expected toxicity risk in the large majority of patients.
The diagnosis of hypogonadism in the male requires the assessment
of the different cellular populations of the testis: Leydig, Sertoli and
germ cells. The classical definition used in the adult male, equating
hypogonadism to low androgen production, is not adequate for male
patients of prepubertal age, a period of life when testosterone levels
are normally very low or undetectable (Rey et al., 2013, Salonia et al.,
2019, Young et al., 2019, Grinspon et al., 2019). Conversely, biomark-
ers of Sertoli cells, the most active component of the prepubertal
testis, are more suitable for the assessment of gonadal function (Josso
et al., 2013). In the present study, we used serum AMH to examine
the potential adverse effect of oncologic therapy in prepubertal boys
with ALL, AML or NHL. AMH is a widely accepted biomarker of the
prepubertal Sertoli cell (Lee et al., 1997, Ankarberg-Lindgren et al.,
2011, Grinspon et al., 2012a, van Brakel et al., 2017, Grinspon et al.,
2018a) and of granulosa cells of small ovarian follicles, proving to be a
useful marker of gonadotoxicity in girls with cancer (Brougham et al.,
2012).
No alteration in serum AMH levels was observed in prepubertal
patients evaluated at least 1 year after the end of chemotherapy, radio-
therapy or even BMT. In adults, Sertoli cells are expected to be resistant
to most chemotherapy agents because they have a mature, stable, non-
proliferating phenotype (Dere et al., 2013, Stukenborg et al., 2018).
Conversely, from birth to the initial stages of puberty, Sertoli cells
proliferate in response to FSH, with two peaks in infancy and peri-
puberty (Sharpe et al., 2003), and then mature in response to andro-
gens (O’Shaughnessy et al., 2009, Edelsztein et al., 2016, Edelsztein and
Rey, 2019), which could make them more susceptible to chemotherapy





























































































































indicate that neither of these processes are significantly affected in
prepubertal boys treated for haematologic malignancies.
In patients of pubertal age, AMH and testosterone levels were
also within the normal range in almost every case. However, when
evaluated beyond Tanner stage G3, i.e. in the context of a reacti-
vated hypothalamic–pituitary–testicular axis, we found an increased
prevalence of compensated testicular dysfunction. This was especially
revealed by an elevation of serum FSH, an indirect sign of Sertoli
cell damage. Concordantly, decreased testicular volume was more fre-
quently observed in patients during the latest pubertal stages (Tanner
G4–5). Whether FSH elevation and reduced testicular volume were
due to a primary Sertoli cell damage or to germ cell depletion cannot
be answered with our data. Sertoli cells proliferate in response to
FSH at the very beginning of puberty, then they mature in response
to the increase in intratesticular androgen concentration (Grinspon
et al., 2018b). Sertoli cell maturation is characterised by a cessation of
mitotic proliferation, a decrease in AMH production and the develop-
ment of subcellular structures involved in cell–cell interaction between
Sertoli cells, driving the development of the blood-testis barrier, and
between Sertoli and germ cells, ultimately responsible for the initiation
and stabilisation of adult spermatogenesis. Both pubertal Sertoli and
germ cell populations contribute to an increase in inhibin B levels
(Andersson et al., 1998, Lahteenmaki et al., 1999, Rohayem et al.,
2017), which exert a negative feedback on pituitary FSH secretion.
One limitation of our study, due to its retrospective design, is the
lack of systematic determination of serum inhibin B in all patients
of the cohort. Nevertheless, as mentioned, both Sertoli and germ
cells contribute to the pubertal increase in circulating inhibin B and
testicular volume. It is therefore difficult to identify the primary damage:
whether primary Sertoli cell dysfunction results in secondary depleted
spermatogenesis or whether primary germ cell damage impacts on
Sertoli cell function and inhibin B secretion. Another limitation of our
study is that semen analysis was not performed in those patients with
long-term follow-up, which precludes us form concluding on potential
fertility impairment. Based on observations made in prepubertal boys
exposed to chemotherapy, reduced spermatogonial quantity may be a
major contributor to explain the elevation of serum FSH (Masliukaite
et al., 2016, Poganitsch-Korhonen et al., 2017). Finally, although some
of our patients received cranial radiotherapy, radiation doses were
always below 30 Gy, which do not increase the risk of hypothalamic–
pituitary–testicular dysfunction (Crowne et al., 2015, Gebauer et al.,
2018).
In this study, our aim was to determine whether the oncologic
treatments used in boys and adolescents with ALL, AML or NHL,
the set of most frequent paediatric cancers, produce a persistent
impairment of the endocrine function of Sertoli and Leydig cells in a
period of life characterised by significant developmental changes in the
testes. To this end, we included in the cross-sectional analysis patients
who had their testicular function assessed at least 1 year after the
end of cancer treatment. We estimated that 1 year was sufficient for
somatic cells to recover after the discontinuation of chemotherapy.
Patients susceptible to receive testicular irradiation were not included.
Owing to the retrospective design of our study, testicular function was
first assessed after variable periods (from 1 to 8 years) after the end of
treatment. We chose to perform the analysis using the first testicular
endocrine assessment available after 1 year had elapsed from the end
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to avoid, whenever possible, the confounding effect of developmental
changes occurring in puberty. Since Sertoli cell endocrine function was
our main focus, we used AMH levels as a direct biomarker. Serum AMH
is normally high in prepubertal boys and declines from Tanner stage G2
onwards due to the physiological inhibition of its expression induced
by intratesticular testosterone (Rey, 1998, Edelsztein et al., 2018). By
selecting the earliest follow-up sample, we reduced the potentially
confounding effect of the physiological decline of AMH due to pubertal
onset. Also, to minimise this effect, we compared hormone levels in our
patients with normative data previously validated for age and Tanner
stage (Grinspon et al., 2011, Grinspon et al., 2012b).
Our series included mainly boys with a diagnosis of ALL, while
the AML and NHL groups were small. The reason for including the
latter, together with patients with ALL, was that drug regimens used
are similar, and our aim was to assess the effect of treatment rather
than the risk of gonadal dysfunction in different childhood cancers.
Although big series of patients with only one diagnosis and only one
treatment would be the ideal, we believe that ours is one of the most
homogeneous series on the subject. Indeed, most series on the effect
of oncologic treatment of childhood on testicular function include adult
patients with many different types of solid and haematologic cancers,
where the treatments are completely different. Intentionally, we did
not include in this study patients with other types of cancer.
Leydig cells, while sensitive to radiation therapy when high doses
(>24 Gy) need to be used (Jahnukainen et al., 2011), seem to be more
resistant to chemotherapy. Indeed, the patients of our cohort showed
no clinically relevant damage of Leydig cell function, as demonstrated
by normal testosterone and LH levels during pubertal development in
the vast majority of cases, with endocrine assessments up to 12 years
after the end of oncologic treatment. A compensated Leydig cell
dysfunction was observed in a few cases, as reflected by LH elevation
whereas a severe hypoandrogenism, requiring testosterone replace-
ment therapy, was seen in only one case with IR ALL, who received
standard chemotherapy. Multiple regression identified high doses of
c-arabinoside as a potential risk factor, although its effect size needs
to be unequivocally proved. In adult males exposed to chemotherapy
during childhood, an increased proportion of hypoandrogenism has
been observed, especially in association with an increased fat mass
and insulin level (Greenfield et al., 2007). The difference between
the prevalence of hypoandrogenism observed in adult survivors of
childhood cancer and the adolescents in our study might reflect the
influence of time or of progressive overweight during adult life. Other
studies have identified up to 31% of Leydig cell failure in adult survivors
of childhood cancer (Hudson et al., 2013). The higher proportion
of Leydig cell dysfunction may be due to the inclusion of all child-
hood cancer types, not only haematologic malignancies, some of
which require very aggressive chemotherapy or radiotherapy affecting
testicular function primarily or secondarily to hypothalamic-pituitary
impairment as a consequence of high-dose cranial radiation protocols
(Crowne et al., 2015).
FSH and LH levels were within the normal range in a large majority
of boys whose treatment ended before the age of 10 years. Given
that gonadotropins may not increase during prepuberty in response
to gonadal damage, we performed a subanalysis in those patients in
whom endocrine assessments were available during puberty. We found
no statistically significant differences in the prevalence of elevated





























































































































nadism, between patients treated before and after 10 years of age.
However, our study may be underpowered in this analysis, since
only part of the cohort treated before the age of 10 years (Group
A) reached advanced puberty during follow-up. In a few cases, the
elevation of gonadotropins was temporary. Long-term follow-up might
identify a subset of patients with transient gonadotropin elevation with
subsequent normalisation by the end of pubertal development.
In conclusion, the regimens used in the treatment of patients with
ALL, AML or NHL in the past two decades seem not to provoke
an overt damage of testicular somatic components, as revealed by
normal levels of AMH and testosterone. However, a mild primary
testicular dysfunction may be observed, usually compensated by slightly
elevated gonadotropin secretion by the pituitary, which generally does
not require hormone replacement therapy.
Supplementary data
Supplementary data are available at Human Reproduction online.
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SUPPLEMENTARY DATA
Supplementary Figure SI Risk stratification and treatment assigned for patients with acute lymphoblastic leukaemia (ALL)
according to the ALL IC-BFM 2002 intercontinental trial. Standard risk (SR) definition required the fulfilment of all the following criteria:
prednisone good response (<1 × 109/l blasts in peripheral blood on day 8 after 7 days of prednisone and one dose of intrathecal methotrexate on day
1), age 1–6 years, initial WBC <20 × 109/l, and M1 (<5% blasts) or M2 (5–25% blasts) marrow on day 15, and M1 marrow on day 33. Intermediate
risk (IR) was defined as prednisone-good response, age <1 year or ≥6 years, and/or WBC ≥20 × 109/l and M1 or M2 marrow on day 15 and M1
marrow on day 33, or SR criteria but M3 (≥25% blasts) marrow on day 15 and M1 marrow on day 33. High risk (HR) definition required at least one of
the following criteria: prednisone poor response (≥1 × 109/l blasts in peripheral blood on day 8 after 7 days of prednisone and one dose of intrathecal
methotrexate on day 1), IR and M3 marrow on day 15, M2 or M3 marrow on day 33, t(9;22) (BCR-ABL), or t(4;11) (MLL-AF4). WBC, white blood
cells.
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SUPPLEMENTARY DATA
Supplementary Table SI Serum gonadotropins, testosterone and AMH levels in 306 healthy males.
AMH (pmol/l) FSH (IU/l) T (ng/dl) LH (IU/l)
Age group n Mean (SD) Mean (SD) Mean (SD) Mean (SD)
......................................................................................................................................................
2.0–8.9 yr 95 782 (461) 0.84 (0.52) 10 (0) 0.10 (0.02)
9–18 yr G1 34 741 (327) 1.64 (0.65) 21.8 (34.6) 0.57 (0.89)
G2 34 419 (301) 2.38 (0.92) 57.5 (164.5) 1.10 (0.88)
G3 42 121 (114) 3.29 (1.64) 223.1 (154.2) 2.37 (1.26)
G4 41 75 (40) 3.80 (1.68) 416.3 (154.2) 3.11 (1.40)
G5 60 92 (50) 3.05 (1.73) 426.0 (158.9) 3.25 (1.52)
Data from: Grinspon RP, Bedecarrás P, Ballerini MG, Iñíguez G, Rocha A, Mantovani Rodrigues Resende EA, Brito VN, Milani C, Figueroa Gacitua V,
Chiesa A et al. Early onset of primary hypogonadism revealed by serum anti-Müllerian hormone determination during infancy and childhood in trisomy
21. Int J Androl 2011;34: e487–e498.
To obtain serum testosterone in nmol/l, multiply by 0.03467. To obtain serum AMH in ng/ml divide by 7.14.
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